Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Final Development Stage For Prolia Reflects Amgen's Eye On Advertising

This article was originally published in The Pink Sheet Daily

Executive Summary

Biotech's roll-out of clinical data on the RANK ligand inhibitor no longer is studies that supported the initial application but studies focused on particular claims or comparative advantages that will improve Prolia's commercial outlook.

You may also be interested in...

Inflamed Language: FDA Sends Harsh Warning Letter To Allergan For Acne Drug

Allergan gets slammed for Aczone Gel promotional claims that FDA says are backed by data "not even nominally statistically significant."

Amgen's Mixed Advisory Committee Votes On Prolia Still Offer A Good Start

The Reproductive Health Drugs Advisory Committee backs Prolia's use to treat osteoporosis in postmenopausal women and bone loss in men undergoing hormone ablation therapy for prostate cancer - though not the largest indication of osteoporosis prevention as well as a REMS.

Denosumab Approval Is “Highly Likely,”– Interview With Amgen’s Perlmutter

In a Jan. 26 interview, Amgen Executive VP for Research and Development Roger Perlmutter talks about denosumab, follow-on biologics and how Amgen is avoiding the size-related innovation drought that many big pharma companies now face.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts